Analysts Offer Predictions for ACXP Q1 Earnings

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for Acurx Pharmaceuticals in a research report issued on Thursday, March 12th. HC Wainwright analyst M. Keller forecasts that the company will post earnings of ($0.59) per share for the quarter. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.70) EPS and Q4 2026 earnings at ($0.75) EPS.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.70.

Several other research analysts have also recently weighed in on ACXP. Wall Street Zen upgraded Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $31.00.

Acurx Pharmaceuticals Stock Down 22.6%

Shares of ACXP opened at $3.88 on Monday. The company has a market capitalization of $11.10 million, a price-to-earnings ratio of -0.69 and a beta of -1.16. Acurx Pharmaceuticals has a 52 week low of $1.33 and a 52 week high of $21.00. The stock’s 50-day moving average price is $2.39 and its 200-day moving average price is $3.80.

Institutional Investors Weigh In On Acurx Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Armistice Capital LLC purchased a new position in shares of Acurx Pharmaceuticals in the 2nd quarter valued at about $551,000. Millennium Management LLC acquired a new position in shares of Acurx Pharmaceuticals during the 4th quarter worth about $103,000. Geode Capital Management LLC purchased a new position in Acurx Pharmaceuticals in the 4th quarter valued at about $31,000. Finally, Jane Street Group LLC acquired a new stake in Acurx Pharmaceuticals in the 4th quarter worth about $27,000. 11.53% of the stock is owned by hedge funds and other institutional investors.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).